GCM
CYTK icon

Graham Capital Management’s Cytokinetics CYTK Stock Holding History

Graham Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-284,700
Closed -$20M – 1103
2024
Q1 		$20M Hold
284,700
– – 0.38% 32
2023
Q4 		$23.8M Buy
+284,700
New +$10.3M 0.53% 34

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Graham Capital Management's CYTK Position: Q1 2026 in Review

Graham Capital Management opened a new position in Cytokinetics (CYTK) in Q1 2026: 4,414 shares worth $291K. The stake represents 0.01% of the portfolio and ranks #829 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in CYTK as recently as Q1 2025.

Graham Capital Management first reported a position in CYTK in Q1 2024 and has held it in 4 quarters since. The position peaked at $643K in Q1 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Graham Capital Management held 4,414 shares of Cytokinetics worth $291K as of Q1 2026.
  • Cytokinetics was a new Graham Capital Management position in Q1 2026.
  • Cytokinetics made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #829 holding.
  • Graham Capital Management first reported a position in Cytokinetics in Q1 2024 and has held it in 4 quarters since.
  • Graham Capital Management's Cytokinetics position peaked at $643K in Q1 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.